Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/14/2021 10/15/2021 10/18/2021 10/19/2021 10/20/2021 Date
8814(c) 8795(c) 8699(c) 8739(c) 8768 Last
1 501 722 1 374 380 1 037 318 1 221 165 926 576 Volume
-0.46% -0.22% -1.09% +0.46% +0.33% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 35 422 M - -
Net income 2021 4 868 M - -
Net Debt 2021 24 833 M - -
P/E ratio 2021 34,8x
Yield 2021 2,34%
Sales 2022 42 847 M - -
Net income 2022 7 894 M - -
Net Debt 2022 20 379 M - -
P/E ratio 2022 22,6x
Yield 2022 2,43%
Capitalization 187 B 187 B -
EV / Sales 2021 5,97x
EV / Sales 2022 4,83x
Nbr of Employees 76 100
Free-Float 96,4%
More Financials
Company
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with... 
Sector
Pharmaceuticals
Calendar
11/12Earnings Release
More about the company
Ratings of AstraZeneca PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ASTRAZENECA PLC
10:00aASTRAZENECA : Credit Suisse remains its Buy rating
MD
09:07aASTRAZENECA : Announces Winners and Recognizes Oncology Change Makers in Third Annual Canc..
BU
08:51aASTRAZENECA : Air Malta Transports Maltese Solidarity to Rwanda; 135,690 AstraZeneca vacci..
AQ
04:44aKAROLINSKA INSTITUTET : Two COVID-19 Vaccine Doses Increase Airway Antibodies After Infect..
MT
03:02aMODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
03:01aASTRAZENECA : Conference Chair Di Morris, AstraZeneca Invites You to Join SMi's 10th Annua..
AQ
01:55aLONDON STOCK EXCHANGE : Nearly half of FTSE 100 companies have no net-zero target, Arabesq..
RE
01:10aASTRAZENECA : India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say
RE
10/19ASTRAZENECA : WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document
RE
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19ASTRAZENECA : Scientists behind AstraZeneca/Oxford vaccine work on Delta-specific jab
AQ
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19ASTRAZENECA : UBS maintains a Buy rating
MD
10/19ASTRAZENECA : India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say
RE
More news
News in other languages on ASTRAZENECA PLC
04:44aKAROLINSKA INSTITUTET : Deux doses du vaccin COVID-19 augmentent les anticorps des voies r..
10/19ASTRAZENECA : dans le vert avec le soutien d'un broker
10/19Gut 54,7 Millionen vollständig geimpft - Quote weiter 65,8 Prozent
10/19VALNEVA : le vaccin Covid de la française plus performant que celui d'AstraZeneca
10/19PLANÈTE BOURSE : La revue de presse du mardi 19 octobre 2021
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 120,53 $
Average target price 137,86 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC19.32%186 853
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986
ELI LILLY AND COMPANY43.51%219 674